Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study-Reference-Cited by-同舟云学术

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study

Published:2017-12-07 Issue:23 Volume:130 Page:2527-2536
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wong Raymond S. M.¹,Saleh Mansoor N.²,Khelif Abderrahim³,Salama Abdulgabar⁴,Portella Maria Socorro O.⁵,Burgess Paul⁶,Bussel James B.⁷

Affiliation:

1. Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong;

2. Hematology & Oncology, The University of Alabama at Birmingham, Birmingham, AL;

3. Hematology Department, Hôpital Farhat Hached, Sousse, Tunisia;

4. Institute for Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany;

5. Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ;

6. Oncology Global Development, Novartis Pharma, AG, Basel, Switzerland; and

7. Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY

Abstract

Key Points Median platelet counts increased to 50 × 109/L or more by week 2 in patients with ITP and were maintained for ≥2 years. Lower platelet counts, more previous therapies, and/or splenectomy resulted in good but somewhat lower responses to eltrombopag.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/23/2527/1404152/blood748707.pdf

Reference46 articles.

1. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro;Chang;Blood,2003

2. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura;Gernsheimer;Hematology Am Soc Hematol Educ Program,2008

3. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP;McMillan;Blood,2004

4. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura;Stasi;Drugs,2008

5. International consensus report on the investigation and management of primary immune thrombocytopenia;Provan;Blood,2010

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Stent Thrombosis in an Immune Thrombocytopenic Purpura Patient;JACC: Case Reports;2024-09

2. Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?;Advances in Therapy;2024-08-20

3. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study;The Lancet Haematology;2024-08

4. Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study;Medicina;2024-07-17

5. Successful use of eltrombopag in ITP post‐splenectomy despite pre‐splenectomy failure;Pediatric Blood & Cancer;2024-07-08